Have a feature idea you'd love to see implemented?
Let us know!
ORMP Oramed Pharmaceuticals Inc
Price (delayed)
$2.31
Market cap
$93.12M
P/E Ratio
21
Dividend/share
N/A
EPS
$0.11
Enterprise value
$51.45M
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and
Highlights
ORMP's debt has shrunk by 99% YoY and by 12% QoQ
The EPS has surged by 127% year-on-year but it has dropped by 78% since the previous quarter
The net income has soared by 127% YoY but it has shrunk by 79% QoQ
The revenue has dropped by 100% year-on-year
The gross profit has plunged by 100% YoY
Key stats
What are the main financial stats of ORMP
Market
Valuations
Earnings
Shares outstanding
40.31M
Market cap
$93.12M
Enterprise value
$51.45M
Price to earnings (P/E)
21
Price to book (P/B)
0.6
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$5.52M
EBITDA
-$5.3M
Free cash flow
-$7.93M
Per share
Balance sheet
Liquidity
EPS
$0.11
Free cash flow per share
-$0.19
Book value per share
$3.84
Revenue per share
$0
TBVPS
$4.04
Total assets
$165.08M
Total liabilities
$9.56M
Debt
$429,000
Equity
$156.44M
Working capital
$137.5M
Debt to equity
0
Current ratio
27.08
Quick ratio
26.99
Net debt/EBITDA
7.86
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
2.3%
Return on equity
2.7%
Return on invested capital
-3.6%
Return on capital employed
-3.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ORMP stock price
How has the Oramed Pharmaceuticals stock price performed over time
Intraday
2.21%
1 week
-1.07%
1 month
-1.49%
1 year
7.94%
YTD
0%
QTD
-5.33%
Financial performance
How have Oramed Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.06M
Net income
$4.47M
Gross margin
N/A
Net margin
N/A
The net income has soared by 127% YoY but it has shrunk by 79% QoQ
The revenue has dropped by 100% year-on-year
The gross profit has plunged by 100% YoY
The operating income is up by 40% year-on-year
Growth
What is Oramed Pharmaceuticals's growth rate over time
Valuation
What is Oramed Pharmaceuticals stock price valuation
P/E
21
P/B
0.6
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 127% year-on-year but it has dropped by 78% since the previous quarter
The price to earnings (P/E) is 53% higher than the last 4 quarters average of 13.7
The P/B is 71% less than the 5-year quarterly average of 2.1
The equity has contracted by 12% from the previous quarter but it has grown by 4.9% YoY
The revenue has dropped by 100% year-on-year
Efficiency
How efficient is Oramed Pharmaceuticals business performance
The company's return on invested capital has shrunk by 161% QoQ but it has surged by 68% YoY
The ROE has soared by 125% YoY but it has plunged by 79% from the previous quarter
The ROA has soared by 125% year-on-year but it has dropped by 77% since the previous quarter
Dividends
What is ORMP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ORMP.
Financial health
How did Oramed Pharmaceuticals financials performed over time
Oramed Pharmaceuticals's total liabilities has shrunk by 88% YoY but it has increased by 18% QoQ
ORMP's current ratio is down by 34% since the previous quarter
ORMP's debt is 100% lower than its equity
Oramed Pharmaceuticals's debt to equity has shrunk by 100% YoY
ORMP's debt has shrunk by 99% YoY and by 12% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.